Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images)
Novartis' first attempt to replicate a stunning cancer result falls flat
A decade ago, Novartis launched a 10,000-person trial to try to turn a rare disease drug into the next heart disease blockbuster. In 2017, the study ultimately failed to show enough cardiovascular benefit to win over regulators, but in the process, Novartis found a surprising and intriguing bit of data: Patients who received the drug were 77% less likely to die of lung cancer than those who didn’t.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
